... review of clinical evidence in Chapter 9. L.1.2. Methods L.1.2.1. Overview of analysis The analysis was based ... Appendix G . Table 1 Overview of clinical trial. L.1.2.2. Approach to modelling Patients in the model ...

... 1,1,1,1,-3,-2,1,2,1,2)) L.6.3. WinBUGS code for inconsistency model for ... 2,0,0,-3,0, 2,1,-1,1,-2, 0)) L.6.10. WinBUGS code for assessment of baseline ...

... C1: Placebo n= 92 C2: Lithium 0.8–1.2 mEq/L (Mean 0.9 mEq/L) n= 90 52 ... C2:Lithium 600–1800 mg/day 0.6–1.2 mEq/L (0.63 mEq/L mean) N=364 104 ... C1: Placebo n= 92 C2: Lithium 0.8–1.2 mEq/L (Mean 0.9 mEq/L) n= 90 52 ...

... 600–900 mg/day serum level 0.6–1.2 mmol/L (mean 0.99 mmol/L) Placebo Lithium 600–900 mg/day serum level 0.6–1.2 mmol/L (mean 0.95 mmol/L) 4 weeks CGI- ... 600–900 mg/day serum level 0.6–1.2 mmol/L (mean 0.99 mmol/L) Placebo Lithium 600– ...

... 2000 mg/day (target serum level 0.6–1.2 mmol/L) (0.80 mmol/L average) 4 weeks MADRS ... Haloperidol 10 mg/day C3: Lithium 0.6–1.2 mmol/L 4 weeks BPRS CGI Unknown Scale - Not reported ...

... 2016 441 Incorrect study design (letter to editor) L.1.2. Facial pain, atraumatic View in own window Reference ...

... 2015 517 Single test at admittance (intellectual disability) L.1.2. Subsequent assessment Table 21 Studies excluded from the ... compulsory diets Wright 2011 510 No relevant outcomes L.3.1.2. Hygiene Table 26 Studies excluded from the clinical ...

... occupation. 7.3.1.2. Dementia 7.3.1.2.1. Acetyl-L-carnitine versus placebo – prevention There was one RCT ( ... and community participation and meaningful occupation. 7.3.1.2.2. Antioxidant versus ... Table 90 Study information table for trials included ...

... Pregnant/Nursing; Abnormal Lab Results Lithium 0.6–1.2 mmol/L (Mean 0.72 mmol/L) C1: Placebo C2: ... Other Conditions Other Mental Health Lithium 0.6–1.2 mmol/L (mean 969 mg/day) Valproate 70–125 mcg/ ...